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Advanced Targeted Nanomedicine
Mohan C M Arachchige, Yana K. Reshetnyak, and Oleg A. Andreev
Department of Physics, University of Rhode Island, 2 Lippit Rd., Kingston, RI, USA
Abstract
Targeted drug delivery has been the major topic in drug formulation and delivery. As 
nanomedicine emerges to create nano scale therapeutics and diagnostics, it is still essential to 
embed targeting capability to these novel systems to make them useful. Here we discuss various 
targeting approaches for delivery of therapeutic and diagnostic nano materials in view of search 
for more universal methods to target diseased tissues. Many diseases are accompanied with 
hypoxia and acidosis. Coating nanoparticles with pH Low Insertion Peptides (pHLIPs) increases 
efficiency of targeting acidic diseased tissues. It has been showing promising results to create 
future nanotheranostics for cancer and other diseases which are dominating in the present world.
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1. Introduction
For a long time people have been working on developing therapeutic agents so that they can 
tune pharmacological and pharmacokinetic properties to treat diseases and get desired 
results. In their continuous quest for food and survival, our ancestors must have experienced 
the effects of natural sources of pharmacologically active chemical substances produced by 
organic and inorganic materials such as plants, fungi, insects, animal excreta, reptiles and 
mineral ores for better or for worse. They must have learnt to extract active ingredients from 
natural resources using crude methods and enhanced to use as pain killers or to heal wounds 
or to treat all types of diseases known to them. Ebers papyrus, dated back to ~ 1500 BC 
provides a detailed description of medical treatments used by ancient Egyptians (Jones, 
2011; Shadlen, 2011). In early as 7 century AD, metal, mineral and herbal based particles 
called Bhashma has been used in Ayurvedic medicine in Indian sub-continent. Modern 
analysis showed that these formulations contained Fe2 O3, FeS2, CuS and SiO2 and also 
particle sizes were regulated in the range of 1-2 μm (Mohaptra and Jha, 2010; Pal et al., 
2014). Undoubtedly, these ancient knowledge had laid the foundation for modern drug 
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formulation and delivery and made a huge breakthrough in this field as the chemical 
analysis became first available to us in 19th century (Ansari and Farha Islam, 2012 ).
While the conventional drugs are still being widely used, the innovation of therapeutic 
nanoparticles has been radically changing the future of drug formulation and delivery (Cai 
and Chen, 2007; Davis, 2008; Gao et al., 2005; Heath et al., 1980; Shi et al., 2010; Zhang et 
al., 2007). Nanoparticles are becoming more popular due to their unique tunable 
physicochemical properties. They have shown promising results in delivery of variety of 
molecules improving the therapeutic index of drugs by enhancing their efficacy and/or 
increasing their tolerability in the body. Nano-carries could also improve the bioavailability 
of water-insoluble drugs, carry large payloads, protect the therapeutic agents from 
physiological barriers, as well as enable the development of novel classes of bioactive 
macromolecules (Swami et al., 2012).
2. Targeted delivery of nanoparticles
Almost a century ago, Paul Ehrlich introduced the concept of targeted drug delivery. It was 
considered as a hypothetical ‘magic bullet’ as an entity consisting of two components — the 
first one should recognize and bind the target, while the second should provide a therapeutic 
action in this target. Currently, the concept of ‘magic bullet’ includes a coordinated behavior 
of three components – drug, targeting moiety and pharmaceutical carrier (Torchilin, 2000). 
Nanoparticles can be designed to have all three properties of the revised version of Ehrlich's 
“magic bullet”, and they could be used as therapeutics and/or diagnostics. When designing 
the nano-drugs it is essential to understand the target region. Target regions could be whole 
organs (heart, lung, brain, liver and etc), tissues (muscle), cells (nerve, dendrite and etc), 
disease specific structures (tumor cells) or cellular components. The efficacy of the 
therapeutics, effectiveness of the diagnostics, safety, affordability and access will measure 
the final success of nanoparticles in medicine in regard to its applied value to the patients.
3. Three major ways of delivery of nanoparticles
Nanoparticle drug delivery systems use the characteristics of disease tissues to selectively 
target their payloads, either by passive, active or physical targeting (Egusquiaguirre et al., 
2012; Petros and DeSimone, 2010).
3.1 Passive targeting
When nanoparticles localize into specific organs or site of disease via biological 
mechanisms, such as RES (reticuloendothelial system) or EPR (enhanced permeability and 
retention) effects, they are known as ‘passive targeting agents’ (Shilo et al., 2012).
RES also called macrophage system or mononuclear phagocyte system, is a class of cells 
which are part of the body's defense mechanisms. If nanoparticles are not protected against 
RES, they will end up in liver, spleen or lymph nodes very soon. Even though this seems to 
be a disadvantage, RES mechanism can be successfully used for mapping liver (Aviv et al., 
2009; Hainfeld et al., 2014; Kim et al., 2007; Kojima et al., 2010; Rabin et al., 2006; Shilo et 
al., 2012), spleen (Boote et al., 2010; Hainfeld et al., 2014; Oh et al., 2011; Rabin et al., 
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2006; Sun et al., 2009; Xiao et al., 2010) and lymph nodes (Aviv et al., 2009; Oh et al., 
2011; Rabin et al., 2006). The information gain from mapping of lymph nodes gives vital 
indications for cancer staging and metastatic potential of tumor, which could prevent 
unnecessary dissection surgery. The EPR effect is very common for most of the solid tumors 
and has been exploiting as a passive mechanism to deliver therapeutic agents. As tumor 
grows its architecture of vasculature become quite abnormal, showing lack of lymphatic 
drainage and leaky blood vessels. This allows the long circulating nanoparticles to 
accumulate in tumor site overtime at higher levels compared to other organs (Acharya and 
Sahoo, 2011; Greish, 2007; Huang et al., 2012; Khalid et al., 2006; Li and Szoka, 2007; 
Maruyama, 2011; Rasmussen et al., 2010; Torchilin, 2010; Wang et al., 2012a).
3.2 Active Targeting
Active targeting uses peripherally conjugated specific targeting moieties for enhanced 
delivery of nanoparticles. The targeting moieties are various ligands including antibodies, 
peptides, aptamers or small molecules that possess high affinity toward unique molecular 
signatures found in diseased tissue to achieve active targeting (Byrne et al., 2008). Three 
general categories of active targeting methods are i) angiogenesis-associated targeting, ii) 
uncontrolled cell proliferation targeting and iii) tumor cell targeting.
Chemical stimulation for angiogenesis is caused by variety of proangiogenic factors such as 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). They 
are the key ingredients of this very complex biological mechanism which is essential for life. 
Pathological angiogenesis or abnormally rapid proliferation of blood vessels is common for 
growth of solid tumors. Therefore the targeting of angiogenesis has become a focus for 
cancer therapeutics (Chung and Ferrara, 2011; Folkman, 2002; Goth et al., 2003; Hicklin 
and Ellis, 2005; Jain, 2002; John and Tuszynski, 2001; Khalid et al., 2006; Seaman et al., 
2007). Thus, the growth factors are attacked by inhibitors of angiogenesis to regulate the 
tumor progression (Folkman, 1996; Mousa, 2000).
Another significant target for cancer cells are the cell proliferation markers. These markers 
are not unique to cancer cells but they are overexpressed in certain cancer cells. The human 
epidermal receptors (HER), transferrin receptors and folate receptors are widely being 
employed. Actively targeting nanoparticles have been using the monoclonal antibodies to 
target overexpressed cell proliferation receptors (Byrne et al., 2008; Gullotti and Yeo, 2009; 
Mamot et al., 2003; Qian et al., 2002; Sudimack and Lee, 2000).
According to the American Cancer Society statistics, in US, it is estimated that more than 
1.6 million new cases of cancer will be diagnosed and more than 0.5 million cancer deaths 
will occur in 2014. The four most common types of cancers that will be diagnosed in 2014 
in the United States are breast in women and prostate in men, lung, and colorectal. Therefore 
targeting of specific tumor cells is becoming another popular area. FDA has already 
approved several monoclonal antibodies for the treatment of specific types of cancers. 
Trastuzumab, a humanized monoclonal antibody against HER-2 which is overexpressed in 
human breast cancer, for the treatment of HER-2-positive metastatic breast cancer was 
introduced in 1998. Panitumumab, a human antibody against EGFR produced in transgenic 
mice (XenoMouse), for the treatment of EGFR-positive colorectal cancer was approved in 
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2006. Avastin, a humanized antibody against VEGF, for the treatment of metastatic 
colorectal cancer was introduced in 2004. Cetuximab, a chimeric antibody directed to EGFR 
(HER-1) for the treatment of advanced colorectal cancer appeared in 2004. Avastin® 
(Genentech, South San Francisco, CA) is a recombinant humanized anti-VEGF monoclonal 
antibody for the treatment of non-small cell lung cancer, metastatic colorectal cancer and 
metastatic breast cancer were approved (Byrne et al., 2008).
The major advantage of the active targeting over the passive targeting is a selective delivery 
of nanoparticles to the specific tumors/pathogenic tissues, which remain in the site of 
disease for an extended period of time, thereby increasing the local accumulation of the 
nanoparticles in the sites of interest. (Baldini et al., 1997; Gonzalez-Angulo et al., 2007; 
Kaufman, 2006; Meacham and Morrison, 2013). However, the heterogeneity and 
adaptability of cancers are difficult to overcome, which makes it problematic to create a 
common cure based on active targeting. Therefore, it is important to identify a universal 
hallmark for majority of cancers or consider use of external physical stimuli as a targeting 
strategy.
3.3 Physical Targeting
In many cases, pathological area differs from normal tissues in certain physical properties, 
such as temperature, lack of oxygen and pH. These natural properties are common for 
majority of cancers independent of origin, and could be exploited as targeting approaches. 
The principle behind use of nanoparticles for physical targeting is that a stimulus, which 
may be applied externally or originate within the pathological site, induces either a physical 
change in the structure of the nanoparticle itself, thereby causing the eradication of the target 
or modulating the rate at which an embedded drug is released. pH, lack of oxygen, 
temperature, ultrasound, electromagnetic radiation and mechanical forces serve as stimuli 
for physical targeting.
3.3.1 Magnetic-sensitive systems—Use of magnetic sensitive nanoparticles was first 
proposed by Widder, Senyi and their colleagues in late 1970s (Senyei et al., 1978; Widder et 
al., 1978). These nanoparticles are primarily fabricated in such way that therapeutic agents 
are attached to, or encapsulated within, a magnetic core or shell by giving capability of 
functionalizing their surfaces. Once functionalized, the nanoparticles are injected into the 
bloodstream, often using a catheter to position the injection site near the target. Powerful 
rare earth magnets are focused over the target site to apply magnetic fields with high-
gradient and the forces affecting the particles. So, the field permits nanoparticles to be 
captured and released at the target. Clinical trials done by Koda et al. to deliver doxorubicin 
hydrochloride showed great deal of success for hepatocellular carcinoma (Koda et al., 2002). 
This method may be effective for targets close to the body's surface, but as the magnetic 
field strength falls off rapidly with distance, sites deeper within the body become more 
difficult to target (McBain et al., 2008). Several groups recently proposed a way to 
overcome this hurdle by implanting magnets near the target site, within the body (Kubo et 
al., 2000; Yellen et al., 2005). However, this method is invasive and not systematic, which 
apply significant restrictions for clinical use. Moreover this method would not target 
metastases, which make cancer a lethal desease.
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Key advantages of magnetic NPs are they can be (i) visualized (super paramagnetic NPs are 
used in MRI);(Andreas et al., 2012; Thorek et al., 2006) (ii) guided or held in place by 
means of a magnetic field; (iii) heated in a magnetic field to trigger drug release or to 
produce hyperthermia/ablation of tissue; (iv) targeted specific locations in the body; (v) 
reduced the quantity of drug needed to attain a particular concentration in the vicinity of the 
target; (vi) reduced of the concentration of the drug at non target sites minimizing severe 
side effects and (vii) used to perform magnetic guided surgeries for surgically impossible 
tumors either due to too hemorrhagic or localized in tissues with high risk of healthy tissue 
injury.
Despite of these advantages they also inherit limitations. MNPs accumulate throughout the 
cross section from the external source to the depth marking the effective field limit which is 
a drawback. Magnetic agglomeration at the absence of magnetic field is tackled by 
superparamagnetic NPs. Creation of smaller NPs, is essential to achieve super-
paramagnetism. As the size becomes smaller, particles’ response to the magnetic field is 
remarkably reduced. As a result of that it makes difficult to direct particles and keep them in 
the proximity of the target while withstanding the drag of blood flow.
3.3.2 Ultrasound-sensitive systems—When nanoparticles are used to target solid 
tumors, homogeneous distribution of most of them in tumor is always questionable. 
Although nanoparticles can extravasate from the blood to the extracellular matrix, they do 
not always travel far away from the blood vessels. Thus, only a small population of cancer 
cells located close to the blood vessels will be exposed to the cytotoxic drugs thus 
minimizing it's therapeutic index. As nanoparticles stay for longer periods of time, they 
could target and bring harm to normal tissues. Researchers have explored ways to use 
ultrasound to enhance the cellular uptake of nanoparticles in the target sites by increasing 
the permeability of the capillary walls, pushing them through the extracellular matrix, 
enhancing the release of the drug from the nanoparticles and improving the cellular uptake.
Escoffre and his colleagues showed on 2D and 3D in vitro models that the focused-
ultrasound not only helps nanoparticles to penetrate into the interior of the tumor, it also 
helps to release drugs to the intercellular space without altering chemical properties 
(Dalecki, 2004; Escoffre et al., 2013; Hagtvet et al., 2011; Pitt et al., 2004b). The use of 
phenomenon of cavitation, which is the formation of bubbles in a medium exposed to 
intense focused ultrasound to disrupt the targeted tissue, is another application of this kind. 
Microbubble-based drug-delivery vehicles can flow through the vasculature into the 
ultrasound focal zone within the tumor region and they can release payloads upon the 
rupture. These bubbles can be also used as imaging contrast agents to improve diagnosis and 
detection of cancer (Dijkmans et al., 2004; Ferrara et al., 2007; Ibsen et al., 2013; Lindner, 
2002; Unger et al., 2001).
Non-invasiveness, the absence of ionizing radiations, and the facile regulation of tissue 
penetration depth by tuning frequency, duty cycles and time of exposure can be identified as 
the main advantages of using ultrasound sensitive systems (Mura et al., 2013). Ultrasound 
can trigger release of drugs from various nanocarriers by destabilization. Ultrasound 
triggered delivery systems has the ability to release drugs into cytosol as result of pore 
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formation in the cell membrane. Therefore they can bypass degenerative endocytotic 
pathway which is especially useful in DNA transfection (Pitt et al., 2004a). Low frequency 
ultrasounds can be used to promote the delivery of some liposomal based drugs through the 
skin to inhibit progression of melanocytic lesions(Tran et al., 2008). However, the increased 
vessel permeability through ultrasound can also impact negatively by promoting metastatic 
dissemination. Possible metastatic dissemination can be minimized by using NPs containing 
agents, which are able to efficiently interact with ultrasonic waves and decrease the 
threshold frequencies of ultrasound waves. Effectiveness of microbubbles based drug 
delivery for tissue targeting may be limited by their short lifespan and absence of 
extravasation. The development of perfluorocarbon (PFC) nanoemulsions and PFC droplets 
functionalized with aptamers, which can be converted into microbubbles under therapeutic 
ultrasounds have significantly improved cellular uptake and/or release of drugs in tumor 
sites(Rapoport et al., 2009).
3.3.3 Temperature-sensitive systems—Above we gave examples of external stimuli 
applied to diseased area to enhance delivery of nanoparticles and/or release of imaging/
therapeutic moieties. Another approach relays on exploration of natural properties or 
microenvironment in diseased tissue. It is observed that certain types of malignant cancer 
(bladder, prostate and etc) (Stefanadis et al., 2001) and some other disease conditions show 
difference in local temperature compared to normal tissues. Understanding of the differences 
of local temperature in pathological sites paved the path to temperature-sensitive delivery 
systems. Long circulating, thermo-sensitive nanocarriers can be fabricated and used to 
exploit micro-environmental temperature differences in diseased sites. For example, in 1978, 
Yatvin et al. first time suggested a method to use temperature-sensitive liposomes to target 
mild hyperthermia in disease sites. Active or passive targeting methods have to be first 
employed to accumulate thermo-sensitive nanocarriers in targeted sites. As the nanocarriers 
accumulate in target sites, carried drugs are released in response to the micro-environmental 
temperature in more controlled manner.
In general, the thermo-sensitive polymers have the ability to swell and de-swell, depending 
on temperature. The two basic types of thermo-sensitive materials are: i) positive 
temperature-sensitive hydrogels that are swollen and hydrated at higher temperatures and 
contract on cooling below the upper critical solution temperature (UCST) and ii) negative 
temperature-sensitive hydrogels that are swollen at lower temperatures and contract on 
heating above the lower critical solution temperature (LCST). Water solubility of the system 
decreases as temperature increases. The latest type of system dominates the literature on 
drug release applications (Ta and Porter, 2013). Upon the introduction of UCST/LCST 
polymers to nanocarrier systems, they gained the ability to actively respond to the 
temperature changes in the microenvironment. As they respond to the environmental 
temperature these systems remarkably change their features such as conformation, solubility 
and hydrophilic/hydrophobic balance to release therapeutic agents in those sites (Fitzpatrick 
et al., 2012).
Injectable thermo-sensitive hydrogel systems are also considered as potential thermo-
sensitive nano-carries owe to their number of advantages, including simplicity of drug 
formulation, protective environment for drugs, prolonged and localized drug delivery, and 
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ease of application. Chitosan and related derivatives, poly(N-isopropylacrylamide)-based 
(PNIPAAM) copolymers, poly(ethylene oxide)/poly(propylene oxide) (PEO/PPO) 
copolymers and its derivatives, and poly(ethylene glycol)/ biodegradable polyester 
copolymers are widely used by researchers to construct injectable thermo-sensitive 
hydrogels (Gong et al., 2013; Lindner et al., 2004; McCoy et al., 2010; Stefanadis et al., 
2001; Yatvin et al., 1978).
DPPC/DSPC are the most common lipids used in making thermo sensitive liposomes. With 
the right lipid composition temperature- dependent fusion of liposomes can be achieved at 
mild hyperthermia region (39 °C- 42 °C) enhancing increased level of drug available at the 
diseased site (Ta and Porter, 2013). Early in vivo work done over a range of tumor models, 
including various carcinomas, sarcomas, and lymph node metastases, and over a range of 
drugs, including adriamycin, methotrexate, bleomycin and cisplatin showed the benefits of 
temperature-sensitive liposomes when use with mild hyperthermia (Iga et al., 1991; 
Maekawa et al., 1987; Nishimura et al., 1990; Tacker and Anderson, 1982; Weinstein et al., 
1979; Yatvin et al., 1981; Zou et al., 1990). Temperature sensitive nano-systems offer 
numerous advantages such as elimination of invasive surgical procedures, the ability to 
bypass physiological barriers, and allowing drugs to reach hard-to-access sites in the body, 
ability to stealth the thermo sensitive systems against immune system and environmental 
degradation and ability to combine this with induced hyperthermia. Owe to extensive studies 
done in these systems over past three decades that gives the capability for wide variety of 
choices to design nanocarriers of desired architectures. Limitations of thermo-sensitive 
nanocarriers can be overcome by combining them with additional stimuli-responsive 
materials.
3.3.4 Targeting hypoxia—Hypoxia (low oxygen concentrations) plays a vital role in 
many tumors by contributing to chemoresistance, radioresistance, angiogenesis, 
vasculogenesis, invasiveness, resistance to cell death, altered metabolism and genomic 
instability. The hypoxic regions often lie surrounding areas of necrosis in solid tumors 
(Brahimi-Horn et al., 2007; Brown and Wilson, 2004; Wilson and Hay, 2011). Hypoxia-
inducible factor (HIF), which is a transcriptional complex, acts as the hypoxia sensor in a 
cell. Overexpression of HIF-α, the regulatory subunit of HIF is a measure of increased 
vascular density, severity of tumor grade, failure of conventional treatment and prognosis. 
Therefore HIF has become an attractive, direct and indirect therapeutic target in recent years 
(Carroll and Ashcroft, 2006; Harris, 2002; Poon et al., 2009). Thambi et al. reported about 
self-assembled nanoparticles called hypoxia-responsive nanoparticles, which can selectively 
release hydrophobic agents under hypoxic conditions (Thambi et al., 2014). In vivo studies 
showed selective accumulation of nanoparticles at the hypoxic regions in tumors compared 
to normal cells.
Development of hypoxia targeting nanoparticles opens new paths to overcome drug delivery 
impediments mentioned earlier. For instance, the brain which demands high amount of 
oxygen is vulnerable to hypoxia as a result of irregularity of the blood flow induced by 
either cardiac failure, traumatic brain injury, brain cancer or subcortical vascular disease. 
Neuronal dysfunction and cell death in major neurodegenerative diseases also have direct 
and indirect links to hypoxia. Since HIF involved in virtually all aspects of the response to 
Arachchige et al. Page 7
J Biotechnol. Author manuscript; available in PMC 2016 May 20.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
hypoxia, HIF based nanocarriers have the potential advantage of simultaneously regulating 
the expression of a large number of genes thus treatment of diseases. However, for HIF 
related therapies it is vital to discriminate between various HIF isoforms (Freeman, 2005; 
Rapisarda and Melillo, 2012). Another potential advantage of hypoxia targeting NPs is the 
ability to treat inaccessible brain tumors, which cannot be achieved through conventional 
surgeries.
3.3.5 Targeting acidity—It's well known that the cancer cells undergo glycolysis even in 
the presence of oxygen which has very significant importance to cancer cells survival and 
proliferation. As a result, high glycolytic activity and production of carbonic and lactic 
acids, which are intensively pumped out cells to keep intracellular pH near neutral, are 
common characteristics of solid tumors. It leads to extracellular acidification of tumor 
microenvironment, which promotes cancer invasiveness and aggressiveness (Gatenby and 
Gillies, 2008; LaMonte et al., 2013; Mahoney et al., 2003; Wojtkowiak et al., 2011). This 
acidic microenvironment is common even for several other diseased tissues, such as 
ischemia, inflammation, arthritis and atherosclerosis. Thus, extracellular acidity might serve 
as a general marker for detecting and targeting of diseased tissue.
pH-sensitive nanoparticle systems are the one of the well-studied delivery systems. These 
systems contain pH sensitive polymers, lipids or peptides such as pHLIPs (pH Low Insertion 
Peptides). Key principle of making pH sensitive fusogenic liposomes is to identify a lipid 
which is stable at physiological pH but destabilized upon acidification following cellular 
internalization, thereby, promoting the release of their contents into the cytosol. First 
generation of such liposomes are designed using the cone shape of 
phosphatidylethanolamine (PE) lipids (Karanth and Murthy, 2007). Cytoplasmic delivery of 
membrane-impermeable therapeutic agents has been improved by the DOPE-based pH 
sensitive liposomes (Chu et al., 1990; Lee et al., 1998; Subbarao et al., 1987). The layer-by-
layer (LbL) nanoparticle assembling technique is developed to prepare pH-sensitive 
nanoparticles. They contain a pH-sensitive outer stealth layer which allows targeting and 
retaining of nanoparticles in acidic tumor regions (Poon et al., 2011). pH sensitive systems 
can be also achieved by the self-assembled surfactants. They are mostly known as niosomes 
and analogues to liposomes. For example, Di Marzio and colleagues reported that the use of 
non-ionic surfactants polysorbate 20 and polysorbate 21 together with cholesterol can form 
highly stable pH sensitive nano-vesicles which have the potential to deliver both hydrophilic 
and hydrophobic therapeutic agents to target sites (Di Marzio et al., 2011). pH sensitive 
systems also show great success for delivering drugs through oral drug administration due to 
vast environmental pH differences in gastrointestinal system (Makhlof et al., 2009, 2011; 
Sonaje et al., 2010). The development of highly pH sensitive NPs to target acidity helps not 
only for treatments but also for diagnosis of wide array of carcinomas and many other 
pathological diseases.
4. pHLIP-technology
The pHLIP technology, which was introduced several years ago, has been showing success 
in targeted drug delivery for cancer and other pathogenic conditions. pHLIP, being a 
membrane peptide, has affinity to cellular membranes and it targets extracellular acidity. In 
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contrast to other pH-sensitive systems, it “senses” acidity at the surface of cancer cells, 
where pH is the lowest due to the reversed pH gradient compared to cells in healthy tissue 
(Chiche et al., 2010).
4.1. Molecular mechanism of pHLIP action
The original pHLIP composed of 36 amino acids is an isolated C-helix of bacteriorhodopsin. 
The water-soluble pHLIP peptide has been observed to behave differently at different pHs 
when it is in the vicinity of the lipid bilayer. The pHLIP binds to lipid bilayer surfaces as an 
unstructured monomer above pH 7, and it spontaneously inserts as an α-helix across lipid 
bilayers at low pH, with a pKapp of 6 (Hunt et al., 1997). The insertion of pHLIP into 
membrane, is reversible and unidirectional, in most cases the C-terminus is translocated 
across the membrane whereas the N-terminus stays outside of the membrane (Reshetnyak et 
al., 2008; Reshetnyak et al., 2007). The opposite occurs for reverse sequence (Weerakkody 
et al., 2013). The insertion mechanism is based on the protonation of Asp/Glu residues 
located in the membrane inserting parts of the pHLIP (Andreev et al., 2014; Barrera et al., 
2011; Hunt et al., 1997; Karabadzhak et al., 2012). The thermodynamics and kinetics of 
pHLIPs membrane-associated folding and insertion has been extensively investigated. 
Peptide's three major forms (in solution, attached to, and inserted across lipid bilayers ) are 
monomeric at peptide concentration less than ~ 7 μM (Reshetnyak et al., 2007). The process 
of insertion and folding (helix formation) is fast and varies from milliseconds to minute 
depending on peptide sequence (Andreev et al., 2010; Karabadzhak et al., 2012). The energy 
of peptide's association with bilayer is about 6-7 kcal/mol (Reshetnyak et al., 2008). As 
pHLIP inserts into the membrane and folds it releases additional energy (about 2 kcal/mol) 
(Reshetnyak et al., 2008), which could be utilized to tether cargo molecules to the surface of 
cancer cells (Fig 1a), or move cell impermeable cargo molecules across the membrane into a 
cell (Fig. 1b). It has been shown tumor targeting of fluorescent, PET and SPECT probes 
attached to the N-terminus of pHLIP (Cruz-Monserrate et al., 2014; Daumar et al., 2012; 
Macholl et al., 2012; Reshetnyak et al., 2011; Vavere et al., 2009; Viola-Villegas et al., 
2014). As biological membrane remains the main barrier for cytoplasmic drug delivery it 
was demonstrated that the energy of membrane-associated folding of pHLIP can be used to 
successfully deliver into cells polar and membrane-impermeable molecules including cyclic 
peptides, toxins, peptide nucleic acids (PNAs) linked to pHLIP's C-terminus via cleavable 
links (An et al., 2010; Moshnikova et al., 2013; Reshetnyak et al., 2006; Thévenin et al., 
2009; Wijesinghe et al., 2011). Over a decade the original pHLIP peptide has given birth to 
more than 20 pHLIP variants and available to use as probing and delivery agent 
(Weerakkody et al., 2013). The ability of pHLIP to probe extracellular acidic environment, 
which is associated with tumors and many other pathological conditions has opened new 
avenues for future drug delivery.
4.2. pHLIP based nanomedicine
Roughly a half a century ago, a British biophysicist and a medical scientist, Alec Bangham 
made a remarkable observation that phospholipids in aqueous systems can form closed 
bilayered structures and named them Bangasomes. Today we call them liposomes. After 
Bangham and his collaborators established the existence of liposomes, the liposomes have 
moved a long journey from being just another exotic entity of biophysical and colloidal 
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science research and became a pharmaceutical carrier of choice for various real-world 
applications, as we outlines in previous sections. As a result of that, now liposomal drugs 
has approved for clinical applications or they are undergoing clinical evaluation (Torchilin, 
2005).
When pHLIP is introduced to the conventional liposomes as a coating moiety (Fig. 1c), it 
allows to enhance the therapeutic value of the liposomes. It was shown that the presence of 
pHLIP on the surface of PEGylated-liposomes enhanced membrane fusion and lipid 
exchange in a pH dependent fashion, leading to increase of cellular uptake and payload 
release (Fig. 1d), and inhibition of cell proliferation by liposomes containing ceramide (Yao 
et al., 2013b). For liposomal drug production and storage the controlling of their size 
becomes a major issue. When liposomes are in storage they could fuse with each other and 
give a poly-disperse liposomal mixture and diminish the desirable properties as nano-
carriers. The same study (Yao et al., 2013a) reveals that liposomes containing just 5% of 
pHLIP lipid composition minimize inter-liposomal fusion and make them stable for several 
days if stored at neutral pH, since pHLIP brings overall negative charge to the surface of 
liposomes at neutral and high pHs. At the same time, drop of a pH leads to the protonation 
of Asp/Glu residues, reduces overall negative charge at the surface of liposomes and 
enhances interaction of pHLIP-coated liposomes with cellular membranes. It was studied the 
interaction between pHLIP-coated liposomes and cells as a function of incubation time of 15 
min vs. 60 min and it was shown existence of different pathways of liposome-cell 
interaction. Predominantly direct liposomal fusion with plasma membrane occurs during 
short incubation period; while during long incubation period, both fusion and cellular 
internalization through endocytosis (most probably, macro pinocytosis) could happen. Since 
pegylation helps to prevent opsonization, it promotes longer circulation of liposomes in 
blood, and enhances probability for liposomes to interact with cell membrane in a pH 
dependent manner. Thus, the pH-sensitive, “fusogenic” pHLIP-coated liposomes could be 
used to selectively deliver various diagnostic and therapeutic agents to acidic diseased cells.
Emmetiere et al. (Emmetiere et al., 2013) (Emmetiere et al., 2013) (Emmetiere et al., 2013) 
introduced dual-delivery approach using pHLIP to tether liposomes to cancer cells in tumor 
(Emmetiere et al., 2013). First, pHLIP was conjugated to the tetrazine (Tz), which is one of 
the bioorthogonally reactive small molecules to form pHLIP-Tz conjugate. pHLIP-Tz was 
injected into mice to selectively label the surface of cancer cells. Then, bioorthogonally 
reactive trans-cyclooctenes coated liposomes containing 18F PET isotope were given as a 
second injection. The long circulating radiolabeled liposomes were accumulated in tumor 
sites mainly via EPR effect, followed the click reaction between tetrazine-pHLIP and trans-
cyclooctenes in liposome coat resulting in covalent conjugation and tethering of liposomes 
to cancer cells. This in vivo click reaction allows achieving high signal/noise ratio, higher 
accumulation of radiolabeled liposomes in tumor site, low nonspecific binding and reduced 
toxicity to kidneys and bone marrow.
According to the World Health Organization statistics the ischemic heart diseases are the top 
leading cause of death, affecting millions of men and women worldwide. Several techniques 
for passive and active imaging and as well as drug delivery to the diseased cardiac tissue 
have been developed during past few years (Galagudza et al., 2010; Scott et al., 2008), 
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which including different types of nanoparticles for drug delivery such as liposomes, drug–
polymer conjugates, polymeric micelles, dendrimers, nanoshells, and nucleic acid-based 
carriers (Torchilin, 2005; Verma et al., 2005; Wang et al., 2008). A study was done to 
evaluate ability of pHLIP-coated liposomes to target ischemic myocardium using two 
murine ischemia models: regional ischemia induced by coronary artery occlusion and global 
low-flow ischemia in isolated hearts (Sosunov et al., 2013). In both models, two candidates 
from the pHLIP family (WT and Var7) were chosen along with pH insensitive kVar7 (K-
pHLIP), which has Lys instead of key Asp/Glu residues and cannot insert into membrane at 
any pH (Weerakkody et al., 2013). It was shown that pHLIP-coated liposomes bind to 
ischemic regions but not to normal myocardium while kVar7 and liposomes coated just with 
PEG (no pHLIP) do not show any targeting (Sosunov et al., 2013). The study ensures that 
pHLIP-coated liposomes have the ability to target ischemic regions with therapeutic agents 
as well as to mark disease regions to assist pHLIP-fluorescent-aided cardiac surgeries.
Another novel approach of pHLIP-coated-liposomes is the delivery of nano-pores to induce 
apoptosis in cancer cells (Wijesinghe et al., 2013). Proper ion balance between intracellular 
and extracellular media is crucial for normal cell functioning. Any alterations in the 
conductance of membranes for ions will lead to cell death. To change cellular ion ballance 
the pore-forming gramicidin A (10 mol%) was delivered to cellular membrane using pHLIP-
coated DOPC liposomes. Liposomes were stable for more than a month in 4 °C. 
Hydrophobic gramicidin A monomers were introduced into pHLIP-coated-liposomes, where 
it makes beta-helices and forms transmembrane porse with diameter of 4-5 Å that can 
transfer monovalent cations through the membrane at rate of 107 cations per second (Hladky 
and Haydon, 1972). As we outlined above, when pHLIP-coated liposomes target cancer 
cells, they either fuse with the plasma membrane or are up-taken by endocytosis and then 
fuse with lysosomal membranes. It leads to delivery of gramicidin A pores (nano-pores) to 
cellular membranes of cancer cells. These nano-pores acidify the intracellular space and 
eliminate the vital Na+/K+ ion balance. This method not only opens pathways to treat acidic 
solid tumors, but also give opportunity to deliver various membrane peptides and proteins to 
the cells, widening the applications in biotechnology and nano-medicine.
Nano-gold particles have also caught attention in pHLIP-nanotechnology. Beneficial 
properties of gold in medicine has been considered for centuries (Wang et al., 2012b). And 
gold has been used in modern science as a contrast agent in electron microscopy. There are 
well-established methods to obtain uniform stable gold nano-structures in the range of few 
nanometers up to couple hundred of nanometers (Papasani et al., 2012). Tuning size and 
shape of nano-gold structures allows to obtain unique physical properties, which can be very 
useful for multiple applications across both therapeutics and diagnostics (Brullot et al., 
2012). Functionalized nano-gold particles are valuable for wide variety of nanomedicinal 
uses and now they are undergoing through evaluations of toxicity (Papasani et al., 2012), 
stability (Gao et al., 2012), pharmacokinetics (Simpson et al., 2013), cellular trafficking (Gu 
et al., 2012; Lin et al., 2012; Sadauskas et al., 2009; Wang et al., 2013), efficacy for gene 
regulation (Sharma et al., 2011) and drug delivery (Gu et al., 2012), and use in photo-
thermal therapies (Letfullin et al., 2011; Raoof et al., 2012).
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Lan et al. showed that nano-gold particles which are 1.4 nm size in diameter conjugated to 
N-terminus of pHLIP can successfully target cancer cells at low pH (Yao et al., 2013a). In 
vivo studies done using mice-tumor models demonstrated high tumor uptake in both 
intravenous and intra-tumoral administration compared to non-functionalized nano-gold 
particles. The beauty of pHLIP-nano gold technology is in its capability of providing the 
specific targeting, enhancing local concentration in tumor mass in homogeneous way while 
remaining in cells for an extended period (several days), by allowing applications of 
radiation therapy and imaging.
Davies and colleagues employed pHLIP to deliver luminescent europium coated 
nanoparticles into platelets (Davies et al., 2012). The 13 nm gold nanoparticles were co-
coated with a europium luminescent, EuL and the pHLIP to give pHLIP.EuL.Au. Human 
platelets are vulnerable to transfection or microinjection. But with this method authors could 
deliver nanoparticles which have roughly 640 lanthanide probes per particle. The result 
shows that the internalization of nanoparticles into the platelets happened only at low pH 
and not at normal pH. The significance of this research is that pHLIP can translocate 
multimodal nanoparticles in a pH dependent manner.
Non-viral vectors are also a hot topic in gene therapy due to their advantages over viral 
vectors such as simplicity of use, ease of large-scale production and lack of specific immune 
response (Niidome and Huang, 2002). Recently it was reported a novel use of pHLIP to 
deliver pDNA to tumor cells (Han et al., 2013a). DGL-PEG-pHLIP were made by 
conjugating the surface of dendrigraft poly-L-lysines (DGLs, generation 3 with 123 amino 
groups per molecule) to the N-terminus of pHLIP followed by electrostatic interactions 
between negatively charged pDNA and positively charged DGL head group of DGL-PEG-
pHLIP to create DGL-PEG-pHLIP/pDNA nanoparticles. Results of in vitro studies showed 
that higher cellular uptake of nanoparticles occurs at low pH (pH 6.0) compared to normal 
pH (pH 7.4) and nanoparticles enter cells mainly by adsorptive mediated endocytosis. The in 
vivo studies also followed the same pattern by showing high tumor uptake of DGL-PEG-
pHLIP/pDNA nanoparticles. It was clear that pHLIP enhanced the pH-controlled 
localization of the nanoparticles in tumors.
Zhao and colleagues (2013) show that pHLIP peptide not only targets acidic tumor micro 
environment but also it can release nanoparticles in a controlled manner to the intracellular 
space. They chose mesoporous silica nanoparticles (MSN), in particular MCN-41, to load 
with doxorubicin. MSN has the attributes of high homogeneous porosity, inertness, 
biocompatibility, high payload capacity and easy surface functionalization capability. The 
MSN particles were attached to the C-terminus of pHLIP by disulfide bond. At low pH (< 
6.5), doxorubicin-loaded pHLIPss-MSN rapidly inserted into the cell membrane and 
translocated MSN into cytoplasm. The disulfide bond was cleaved in cytoplasm to release 
doxorubicin.
Table 1 summarizes the current pHLIP applications in nanotechnology we discussed above.
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5. Conclusion
There are several challenges for targeted nano drug delivery systems to overcome. Still most 
of these drug systems undergo in vitro and in vivo testing using animal models. Therefore 
their relevancy to the real patients has to be evaluated extensively. Each nano drug platform 
is distinctive and need to be assessed experimentally as new system, which is strenuous. 
Nanoparticles stability, size uniformity, controlled drug release rate, sterile preparations in 
large scale and manufacturing cost have to be addressed in order to make them available to 
the market. But with recent scientific advances, next ten years it is expected to see large 
number of targeted drug delivery systems based on nanoparticles in the market. pHLIP 
nanotechnology has been showing its potential capability to address most of the challenges 
mentioned above. pHLIP technology used alone or combined with other approaches might 
lead to new formulations translatable to clinics.
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EGFR epidermal growth factor receptor
DGLs dendrigraft poly-L-lysines
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Highlights
• Nanomaterials are used to target both imaging and therapeutic agents
• Targeting a tumor environment might better address issue of tumor 
heterogeneity
• pHLIP senses acidity on the surface of cells
• pHLIP targets nanomaterials to acidic diseased tissue
• pHLIP promotes cytoplasmic delivery of nanomaterial's payloads
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Fig.1. 
Different applications of pHLIP for targeting of acidic tissues. Tethering of cargo molecules 
to the surface of cells (a). Cytoplasmic delivery of cargo molecules and it's release by break 
of cleavable link (shown in blue) (b). Assembly of multifunctional pHLIP-coated liposomes 
containing polar (green) and hydrophobic (yellow) payloads (c). Schematic presentation of 
interactions of lipid bilayer of the pHLIP-coated multifunctional liposomes with plasma 
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membrane of a cell (presentation of liposome in the endosome is schematic and not in a 
scale) (d).
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Table 1
Current pHLIP applications in nanotechnology
pHLIP nanotechnology How it works Administration Authors
PEGylated-liposomes containing ceramide Increase ceramide levels in cancer tissues 
promote cell death and tumor inhibition
In-vitro and In-vivo (Yao et al., 2013c)
pHLIP-Tz conjugates and trans-cyclooctenes 
coated liposomes containing 18F PET isotopes
Tetrazine(Tz) labeled cancer cells are 
targeted by trans-cyclooctenes coated 
liposomes to radio label the tumor site
In-vivo (Emmetiere et al., 
2013)
WT and Var7 coated liposomes pHLIP coated liposomes binds to ischemic 
regions and assist pHLIP-fluorescent -
aided cardiac surgeries
In-vivo (Sosunov et al., 
2013)
pHLIP liposomal nano-pores Hydrophobic gA is delivered to cancer 
cells to form channels in cell membrane to 
destroy ion balance and induce apoptosis
In-vitro (Wijesinghe et al., 
2013)
pHLIP nano-gold particles Homogeneous accumulation of gold in 
tumor sites allow radiation therapy and 
imaging
In-vivo (Yao et al., 2013a)
Eu coated pHLIP nanoparticles At low pH, more lanthanide probes can be 
internalized to human platelets breaking 
the targeting barrier
In-vitro (Davies et al., 2012)
pDNA nanoparticles High uptake of DGL-PEG-pHLIP/pDNA 
in tumors
In-vivo, In-vitro (Han et al., 2013b)
dox MSNs Dox are loaded to porous silica 
nanoparticles and deliver to cancer cells 
using pHLIP
In-vitro (Zhao et al., 2013)
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